-
公开(公告)号：US20220096651A1
公开(公告)日：2022-03-31
申请号：US17421365
申请日：2020-01-28
发明人： Andreia COSTA , Rupesh AMIN , Jenna BAILEY , Samriti BEDI , Brian BELMONT , Aye CHEN , Stephen Jacob GOLDFLESS , Eric JEFFERY , Yue JIANG , Yeonjoo OH , Madeline WILLIAMS , Collin HAUSKINS , Catherine SIERRA
摘要： Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1-binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.
-
公开(公告)号：US20190225692A1
公开(公告)日：2019-07-25
申请号：US16338452
申请日：2017-10-03
发明人： James SISSONS , Cameron BRANDT , Alexandra CROFT , Allen EBENS , Haley PEPER , Dean Y. TOY , Brian BELMONT , Stephen GOLDFLESS , Yue JIANG , Timothy JOHNSTONE , David KOPPSTEIN , Hieu NGUYEN , Blythe SATHER , Sonia TIMBERLAKE
IPC分类号： C07K16/28 , A61P31/20 , C07K14/725 , A61K39/12
摘要： Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
-
公开(公告)号：US20240226298A1
公开(公告)日：2024-07-11
申请号：US18537696
申请日：2023-12-12
发明人： Ruth Amanda SALMON , Douglas JONES , Brian BELMONT , Madeline WILLIAMS , Rebekah TURK , Eric William JEFFERY , Andres ALVAREZ , Yue JIANG , Gabriela DIAZ , Thomas COX , Chia-Yung WU , Tiffany HUELAR , Jon JONES , Stephanie BUSCH , Cedric CLEYRAT
IPC分类号： A61K39/00 , A61K47/68 , A61P35/00 , C07K14/725 , C07K16/28
CPC分类号： A61K39/464417 , A61K39/4611 , A61K39/4631 , A61K39/464412 , A61K47/6849 , A61P35/00 , C07K14/7051 , C07K16/2803 , C07K16/2878 , C07K2317/24 , C07K2317/31 , C07K2319/02 , C07K2319/03
摘要： Provided are B cell-activating factor receptor (BAFF-R)-binding molecules, in particular, to human antibodies specific for BAFF-R, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for BAFF-R. Also provided are CARs which contain extracellular binding domains that bind to BAFF-R and B-lymphocyte antigen CD19 (CD19), genetically engineered cells expressing such CARs, and uses thereof in adoptive cell therapy.
-
公开(公告)号：US20220225597A1
公开(公告)日：2022-07-21
申请号：US16624766
申请日：2018-06-29
发明人： Eric Martin CHADWICK , Ronald James HAUSE, JR. , Yue JIANG , Hyam I. LEVITSKY , Ruth Amanda SALMON , Rafael Angel PONCE , Neis Eric OLSON
IPC分类号： A01K67/027 , G01N33/50 , A61K31/675 , A61K35/17 , A61K49/00 , C07K16/28 , C07K14/705 , C07K14/725
摘要： Provided herein is a model, in particular a mouse model, for assessing or evaluating toxicity to an immunotherapy, for example a therapeutic cell therapy, such as a cell therapy containing engineered cells, such as T cells, expressing a recombinant receptor, e.g. a chimeric antigen receptor (CAR). Also provided is a method for generating the mouse model. Also provided herein are methods of use for the mouse models of toxicity, such as to evaluate modified or alternative immunotherapies, and/or to evaluate test agents, including agents to assess as potential interventions to reduce, prevent, or ameliorate toxicity to immunotherapy in human subjects and/or for use in combination with an immunotherapy, e.g. CAR−T cell therapy.
-
公开(公告)号：US20220008477A1
公开(公告)日：2022-01-13
申请号：US17292363
申请日：2019-11-07
发明人： Jens HASSKARL , Stanley R. FRANKEL , Michael PORTS , Michael POURDEHNAD , Heidi JESSUP , Yue JIANG , Jim Shi Xiang QIN , Neha SONI , Melissa WORKS
摘要： The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.
-
公开(公告)号：US20230178239A1
公开(公告)日：2023-06-08
申请号：US17924652
申请日：2021-05-12
发明人： Ronald James HAUSE, JR. , Yue JIANG
摘要： The present disclosure relates to methods for identifying features, such as attributes of subjects, therapeutic cell compositions, and input compositions used to produce therapeutic cell compositions, associated with clinical responses of subjects, e.g., patients, following treatment with the therapeutic cell composition in connection with a cell therapy. The cells of the therapeutic cell composition express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods provide for the identification of features associated with clinical responses. In some embodiments, the methods can be used to determine (e.g., predict) a subject's response to treatment with the therapeutic cell composition.
-
公开(公告)号：US20220412954A1
公开(公告)日：2022-12-29
申请号：US17774464
申请日：2020-11-04
IPC分类号： G01N33/50 , A61K35/17 , C07K14/725 , C12N5/0783 , G16H20/17 , G16H50/70
摘要： Provided are methods for determining or predicting attributes of therapeutic cell compositions in connection with cell therapy. The cells of the therapeutic cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods provide for the identification of correlations between input composition (e.g., starting material derived from subjects for producing a cell therapy) attributes and therapeutic cell composition attributes.
-
公开(公告)号：US20210284709A1
公开(公告)日：2021-09-16
申请号：US16652379
申请日：2018-09-28
发明人： Cameron BRANDT , Brian BELMONT , Christopher BORGES , Stephen Michael BURLEIGH , Alexandra CROFT , Stephen Jacob GOLDFLESS , David Jeffrey HUSS , Yue JIANG , Timothy G. JOHNSTONE , David KOPPSTEIN , Hieu NGUYEN , Christopher Heath NYE , Haley PEPER , Blythe D. SATHER , Sonia TIMBERLAKE , Dean Y. TOY , Queenie VONG , Gordon Grant WELSTEAD , James SISSONS
摘要： Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
-
公开(公告)号：US20210128619A1
公开(公告)日：2021-05-06
申请号：US17089594
申请日：2020-11-04
发明人： Timothy CAMPBELL , Ronald HAUSE , Kristen HEGE , Yue JIANG , Shari KAISER , Ethan THOMPSON , Jaymes FULLER , Nathan MARTIN , Rong LIU , Justine DELL'ARINGA
摘要： Provided herein are uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.018 秒)
